{"ticker": {"uuid": "6e03991b-5289-49bd-8f4a-2d4be29f95b7", "symbol": "NUVL", "name": "Nuvalent Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Deerfield holders cash out of Nuvalent (NUVL) at $124 per share", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPVkNPN1RRdXJWaWhvc2xLcnduRTEtb25zSk1CdnBHVzRkNTlRM1lZSThnQzJUaFRsNGstTnhsemRQdDhuMW02Zkc3Y0RWdkdwOUNmM3BTTWYxX0ZnM2xoTXV5c0d4Zmk2dmROZWViekgxTEhoQ3AzRWJvTnpNWU01RXBzeXgtOWhuaVdncUMxenRjNFFDWUpnSDZDcE1zRG9GcUtPdHlDdlY1QQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T19:27:52+00:00", "published_display": "17 Jul 2026 19:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deerfield group reports 0% ownership in Nuvalent (NUVL) Class A shares", "summary": "A Deerfield-affiliated investor group, led by James E. Flynn, has filed an amended Schedule 13G (Amendment No. 7) for Nuvalent, Inc. (NUVL). The filing indicates that the group now beneficially owns 0 shares of Nuvalent Class A common stock, translating to 0.0% of the class. This", "url": "https://www.stocktitan.net/sec-filings/NUVL/schedule-13g-a-nuvalent-inc-amended-passive-investment-disclosure-558e68760ceb.html", "source_name": "Stock Titan", "published_at": "2026-07-17T19:39:53", "published_display": "17 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nuvalent, Inc. (NUVL) director\u2019s RSUs and options canceled for $124 cash rights in GSK merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOYXFtRF95X3lLRmxCbHJLRVNMR0hrU1BTNUl5RDRDbm51OWNaTm5rMUxCWVJpSmxNUVB4RUp1bmxHblBUWGtXSGFoOU9sc1Z5dVpkcVNVbmJTTGpfQW80eEo3YjlqdTV0MnJRaHBMSDhwOXVDRktMcVcxOHNCVmpMR2NUSXJlY05sVEVmYXBLdkVOY3hqbUxsS2NXSTlONzYxcnU0bGE2ZUhwQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T23:03:48+00:00", "published_display": "15 Jul 2026 23:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK\u2019s $124-per-share Nuvalent, Inc. (NUVL) deal reshapes CMO equity", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQS1R5THVDQkpLRWlVQ3g1ajR6Y01qcF9YU3pOQ3pmb2xZekI0Nks4bkhlRXlwa3R6NlFoXzVRbVRQNHBUejRYOFZkRHlMSXp5ZTRqb05Hek5NdnhRN2dCS1BFV1dHZmdyY1BwZTlXVkZmODJZdnd0N2Mtc1pVNjdyY1dqMDN6Rm5kMkVBcWtzWjdUY2ZoY0RiUWY0T1ktNTdHUlNBbTRVenVtQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T22:58:19+00:00", "published_display": "15 Jul 2026 22:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent, Inc. (NUVL) officer exits via $124-per-share cash tender", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQU0FmTkdEOXF4U0VJZW5HaWRxTnFqQkNJeE5KTjBnZkF4dGJ0d1VpczRHcFZURlY5czFkRDhud3R2Vmp0WmVJM0I2RlFlaUVkM25ySTAya2Rib2lsazhDMTBOZU1mNGJvaHpIeUs0ZmloMzJTdktTZUxaZFNyNldKYXRlN3N4QjdqRXVHS1BXYS13NVlZQlVHM0ZUUU9vQkhsQ2c3dVV3a3Nudw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T22:51:21+00:00", "published_display": "15 Jul 2026 22:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NUVL) CLO exits equity via $124-per-share GSK tender offer and merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPb0NKb3k4MV9jUGZ3Qk1yc19ORjBKZ0g1VW5LM1hQLUw3U3A1bHZmbW5SckhJeDBabmljcDR2XzhHYzVxeWJtZTNvVmZRNGJnSWlQbXZ0MnJncVp3WGV4dGx2TmxrM1ZpVUQzZXlKVmNDQkNHeTdLMlRRbllvRkhsVFRQTklubHNtckNkbWpuY3c4eUtjRTRiQzg1ZEllTzV4VmNoeVpBaEJHZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T22:42:56+00:00", "published_display": "15 Jul 2026 22:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Nuvalent, Inc. Insider Trading Activity", "summary": "Nuvalent, Inc.'s Chief Development Officer, Darlene Noci, reported significant merger-related equity transactions. These involved the tender of 17,017 shares of Class A Common Stock at $124.00 per share as part of a tender offer by a GlaxoSmithKline affiliate, which was followed ", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-ca243ab0ebcf.html", "source_name": "Stock Titan", "published_at": "2026-07-15T23:10:23", "published_display": "15 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent, Inc. (NUVL) CEO equity converted in $124 GSK tender offer", "summary": "Nuvalent, Inc.'s President and CEO, James Richard Porter, converted all his equity holdings, including 203,529 Class A shares, RSUs, PSUs, and stock options, into cash as part of a tender offer and subsequent merger with an affiliate of GSK plc. The shares were tendered at $124.0", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-0ecfb9620971.html", "source_name": "Stock Titan", "published_at": "2026-07-15T23:10:23", "published_display": "15 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent, Inc. (NUVL) director tenders stock in $124 GSK cash buyout", "summary": "Nuvalent, Inc. director Sapna Srivastava has disposed of equity tied to a cash tender offer and merger with a GlaxoSmithKline affiliate. She tendered 5,146 shares of Class A Common Stock at $124.00 per share, and had 3,444 restricted stock units and several stock option grants ca", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-c04b38e362af.html", "source_name": "Stock Titan", "published_at": "2026-07-15T23:10:23", "published_display": "15 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent, Inc. (NUVL) CFO details tender offer and award cash-outs", "summary": "Nuvalent, Inc. CFO Alexandra Balcom reported significant equity transactions stemming from a merger with a GlaxoSmithKline affiliate. She tendered 44,433 shares for $124.00 per share and saw restricted stock units and stock options cancelled and converted into cash at the same of", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-c76d095bc323.html", "source_name": "Stock Titan", "published_at": "2026-07-15T23:10:23", "published_display": "15 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NASDAQ: NUVL) director logs $124 tender-offer disposals", "summary": "Nuvalent Director Wheeler Cameron reported the disposition of 5,146 Class A shares at $124.00 each, along with 3,444 RSUs and several stock option grants, related to GlaxoSmithKline's tender offer and subsequent merger. These transactions resulted in Cameron's reported holdings i", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-691071d94372.html", "source_name": "Stock Titan", "published_at": "2026-07-15T22:10:23", "published_display": "15 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NUVL) director exits equity as GSK affiliate pays $124 per share", "summary": "Nuvalent's director, Grant C. Bogle, cashed out his equity holdings in connection with the company's acquisition by a GlaxoSmithKline affiliate. The acquisition involved a tender offer at $124.00 per share, resulting in Nuvalent becoming a wholly owned subsidiary. Bogle disposed ", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-e1cd69ad784e.html", "source_name": "Stock Titan", "published_at": "2026-07-15T22:10:23", "published_display": "15 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NUVL) director equity cashed out in $124 GSK buyout", "summary": "Nuvalent's director, Anna Protopapas, reported dispositions of her equity holdings in connection with GlaxoSmithKline's tender offer to acquire all outstanding Nuvalent stock for $124.00 per share. Her 5,146 Class A shares, 3,444 restricted stock units, and multiple stock options", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-2f5438f80665.html", "source_name": "Stock Titan", "published_at": "2026-07-15T22:10:23", "published_display": "15 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK Completes $10.6 Billion Acquisition of Nuvalent", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/gsk-completes-10-6-billion-141637255.html", "source_name": "MT Newswires", "published_at": "2026-07-15T14:16:37+00:00", "published_display": "15 Jul 2026 14:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GlaxoSmithKline LLC closes $10.6B Nuvalent (NUVL) all-cash tender and merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOSm54SkI0VWRyYVh5Q0M1RTRsMlVLejNJMVg2QUJiQjdKRDNRc0UtNEVONzhfbG5jUUxrZHYzNWxEZzdZNFYzMGp6NlZzNGdxTHpYUXBkTy1namQ1RFNScXRfSDNRQWJWRHVzdXE4SVFLVkI4SFhXcEF5anZEc1lGVlVRajV4RmZtNDE5dWxlcllscjBGeFl4V0lQcVlHWmd6NVpB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T13:03:50+00:00", "published_display": "15 Jul 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent Inc. (NASDAQ: NUVL) Holders Tender 91% in $124 GSK Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNWXVyanV2VXQzYXZYNlBJS2ZoWUxOZUZCRHNrdUZzNm1ZSUdhOE1JYlh5WDJHaVFLVzMtWGR4NzRYdXAyZ1dkcTdXU0JEd2ZrVXQ0ZmxjSXFUUUZmTmlWZnN2X2g1WnZPVXNWY3FYUURZODZOQTE2TDBpLW9PYXFaZXpQc3pjaGw2d2RYSnFRZnZHVGx1U3JZbDZtY0Z0cjBOVTFzSVhNdE45bW5XWHltNDZwc0tuTjZT?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T13:02:07+00:00", "published_display": "15 Jul 2026 13:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NASDAQ: NUVL) moves to remove Class A stock from Nasdaq", "summary": "Nuvalent, Inc. (NASDAQ: NUVL) has filed a Form 25 to delist its Class A Common Stock from the Nasdaq Stock Market LLC, indicating a voluntary withdrawal from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. This action signifies that both Nasda", "url": "https://www.stocktitan.net/sec-filings/NUVL/25-nse-nuvalent-inc-sec-filing-f4ab8a359c16.html", "source_name": "Stock Titan", "published_at": "2026-07-15T13:43:45", "published_display": "15 Jul 2026 13:43", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NASDAQ: NUVL) tender offer clears $124 cash merger path", "summary": "Nuvalent, Inc. announced the final results of the tender offer by Harmony Row Acquisition Co., a subsidiary of GlaxoSmithKline LLC, to acquire all outstanding shares for $124.00 per share. Approximately 91.3% of Nuvalent's shares were validly tendered, satisfying the minimum tend", "url": "https://www.stocktitan.net/sec-filings/NUVL/sc-14d9-a-nuvalent-inc-amended-tender-offer-recommendation-f25304ac2498.html", "source_name": "Stock Titan", "published_at": "2026-07-15T12:43:45", "published_display": "15 Jul 2026 12:43", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nuvalent CSO Henry Pelish sells $261,362 in stock By Investing.com", "summary": "Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold 2,111 shares of Class A Common Stock for $261,362, executed under a Rule 10b5-1 trading plan to cover tax obligations. This sale occurred as Nuvalent shares approached a 52-week high, coinciding with GSK's announced acqui", "url": "https://m.au.investing.com/news/stock-market-news/nuvalent-cso-henry-pelish-sells-261362-in-stock-93CH-4528403?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-07-11T02:39:46", "published_display": "11 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent CSO Henry Pelish sells $261,362 in stock", "summary": "Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold 2,111 shares of the company's Class A Common Stock for $261,362 on July 9, 2026. This transaction was part of a pre-established trading plan, often used to cover tax obligations from equity awards, and occurred as Nuvalen", "url": "https://m.uk.investing.com/news/stock-market-news/nuvalent-cso-henry-pelish-sells-261362-in-stock-93CH-4766405?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-10T21:10:59", "published_display": "10 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent, Inc. (NUVL) \u2014 HSR waiting period cleared; $124/ share cash offer remains subject to closing conditions", "summary": "Nuvalent, Inc. (NUVL) announced that the Hart-Scott-Rodino (HSR) Act waiting period for its tender offer with Harmony Row Acquisition Co./GlaxoSmithKline LLC expired on July 9, 2026. This satisfies one key closing condition for the $124 per share cash offer, though the overall of", "url": "https://www.stocktitan.net/sec-filings/NUVL/sc-14d9-a-nuvalent-inc-amended-tender-offer-recommendation-e9e43c76efb1.html", "source_name": "Stock Titan", "published_at": "2026-07-10T19:39:46", "published_display": "10 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent Inc. (NUVL) \u2014 GSK\u2019s Harmony Row clears HSR; $124 cash offer proceeds", "summary": "The article reports that the HSR waiting period for GSK\u2019s Harmony Row Acquisition Co.'s tender offer to acquire Nuvalent Inc. (NUVL) has expired, satisfying a key regulatory condition. Harmony Row Acquisition Co., GlaxoSmithKline LLC, and GSK plc are offering $124.00 per share in", "url": "https://www.stocktitan.net/sec-filings/NUVL/sc-to-t-a-nuvalent-inc-amended-third-party-tender-offer-626639507bad.html", "source_name": "Stock Titan", "published_at": "2026-07-10T13:11:25", "published_display": "10 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NUVL (NASDAQ: NUVL) insider sale notice for 2,111 Class A shares", "summary": "Nuvalent, Inc. (NASDAQ: NUVL) has filed a Form 144 indicating a proposed sale of 2,111 shares of Class A Common Stock, valued at $261,358.43, related to Restricted Stock Unit Vesting on July 9, 2026. The filing also revealed that 3,093 shares, totaling $323,169.86, were sold in t", "url": "https://www.stocktitan.net/sec-filings/NUVL/144-nuvalent-inc-sec-filing-58d06110a8e9.html", "source_name": "Stock Titan", "published_at": "2026-07-10T08:41:59", "published_display": "10 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent president and CEO Porter sells $3.7m in shares By Investing.com", "summary": "Nuvalent (NASDAQ:NUVL) President and CEO James Richard Porter sold 30,000 shares of Class A Common Stock for approximately $3.71 million on July 6, 2026, while concurrently exercising options to acquire 30,000 shares. This transaction occurred as the stock traded near its 52-week", "url": "https://m.in.investing.com/news/stock-market-news/nuvalent-president-and-ceo-porter-sells-37m-in-shares-93CH-5488140?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-07-08T23:11:12", "published_display": "08 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NUVL) CEO executes 30K-share option exercise and open-market sale under 10b5-1 plan", "summary": "Nuvalent, Inc. President and CEO James Richard Porter executed a pre-planned transaction, exercising options for 30,000 shares of Class A Common Stock at $18.93 per share and simultaneously selling those 30,000 shares in the open market at a weighted average price of $123.72 per ", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-e51a3734a597.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:11:12", "published_display": "08 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC discloses 1,417,590 shares in Nuvalent (NASDAQ: NUVL)", "summary": "FMR LLC has filed an Amendment No. 5 to Schedule 13G/A, revealing a beneficial ownership of 1,417,590.47 shares of Nuvalent Inc. Class A common stock, which accounts for 1.9% of the total class. The filing indicates sole voting power over 1,402,750 shares and sole dispositive pow", "url": "https://www.stocktitan.net/sec-filings/NUVL/schedule-13g-a-nuvalent-inc-amended-passive-investment-disclosure-7149bc8d4077.html", "source_name": "Stock Titan", "published_at": "2026-07-08T14:09:34", "published_display": "08 Jul 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent(NUVL.US) Officer Sells US$3.71 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPWF8wZ1NDanFCWGRyWVZjd2VtSFZlR0dXZ0lqbUs2akRMZ2V5NVR4RmVuLXFmRmVmbk1KSmR0T2R6MUtEdHNuXzhBVnpCTDRzaF9xWGJXZ0dKWWNnclhuNjFoeVMtcWQ5Y1J1MEVUZEpKTjNwZXROckZXai1RWVFWekJidnNuVzVaSlZUZWlsYW1qcFpTVUI4ZWVubFBFQQ?oc=5", "source_name": "Moomoo", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NUVL) supplements disclosures as $124 cash offer proceeds", "summary": "Nuvalent, Inc. amended its Schedule 14D-9 to provide supplementary disclosures regarding the recommended $124.00 per share cash tender offer by a GlaxoSmithKline subsidiary. This amendment includes additional financial details, management forecasts, and Centerview valuation analy", "url": "https://www.stocktitan.net/sec-filings/NUVL/sc-14d9-a-nuvalent-inc-amended-tender-offer-recommendation-6dfc2781654d.html", "source_name": "Stock Titan", "published_at": "2026-07-07T19:09:34", "published_display": "07 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NUVL) CFO sells 11,430 shares and exercises options under plan", "summary": "Nuvalent, Inc.'s CFO, Alexandra Balcom, exercised stock options for 11,430 shares and subsequently sold the same number of shares (11,430) at a weighted average price of $123.58 per share. These transactions were executed on July 1, 2026, under a Rule 10b5-1 trading plan adopted ", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-03b6d980e834.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:12:11", "published_display": "06 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NUVL) CDO exercises options and sells 23,000 shares", "summary": "Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options for 23,000 shares of Class A Common Stock on July 1, 2026, at exercise prices of $72.35 and $18.93 per share. Immediately after, she sold all 23,000 shares in an open-market transaction at a weighted aver", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-8096d5f30480.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:12:11", "published_display": "06 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NUVL (NASDAQ: NUVL) Form 144 lists insider sale of Class A Common", "summary": "Nuvalent, Inc. (NUVL) has filed a Form 144 with the SEC, indicating a proposed insider sale of Class A Common shares via NQ Stock Options, with J.P. Morgan Securities LLC named as the broker. The filing also details multiple past sales attributed to Alexandra Balcom, occurring be", "url": "https://www.stocktitan.net/sec-filings/NUVL/144-nuvalent-inc-sec-filing-99795911a530.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:35", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider at Nuvalent (NUVL) exercises options and sells 5,500 shares", "summary": "Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options to acquire 5,500 shares at $27.85 per share and subsequently sold those 5,500 shares in the open market for a weighted average price of $123.51 per share. These transactions were conducted under a pre-arr", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-b000314d9e63.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:35", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share", "summary": "GSK plc has launched a tender offer to acquire Nuvalent, Inc. for $124 per share in cash, following a merger agreement signed on June 9, 2026. This move represents a significant step in GSK's strategic acquisitions. Additionally, GSK's ViiV Healthcare has introduced the PrEP Wisd", "url": "https://www.insidermonkey.com/blog/gsk-plc-gsk-launches-tender-offer-to-acquire-nuvalent-inc-for-124-per-share-1792040/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-30T13:40:25", "published_display": "30 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Nuvalent, Inc. Class A \u2013 FWB:5AX", "summary": "This article provides financial information for Nuvalent, Inc. Class A, specifically its enterprise value to revenue (forward) metric. The content indicates that the market was closed and no trades were made for this stock. The data is provided by ICE Data Services and FactSet Re", "url": "https://www.tradingview.com/symbols/FWB-5AX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T17:40:53", "published_display": "28 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Nuvalent, Inc. Class A \u2013 FWB:5AX", "summary": "This article provides financial information for Nuvalent, Inc. Class A, traded on the Frankfurt Stock Exchange (FWB:5AX). It specifically highlights the \"Price to book forward\" metric. The content itself seems to be a placeholder or a snippet from a financial data platform, showi", "url": "https://www.tradingview.com/symbols/FWB-5AX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T01:40:55", "published_display": "26 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent, Inc. Class A Actuals & Estimates (NASDAQ:NUVL)", "summary": "This article provides an overview of Nuvalent, Inc. (NASDAQ: NUVL) stock's actuals and estimates, including its current stock price, historical performance, analyst forecasts, and various financial metrics. It details the company's market capitalization, earnings per share, reven", "url": "https://www.tradingview.com/symbols/NASDAQ-NUVL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:39:25", "published_display": "26 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Nuvalent, Inc. Class A \u2013 FWB:5AX", "summary": "This article provides financial information for Nuvalent, Inc. Class A, traded on the Frankfurt Stock Exchange under the symbol FWB:5AX. It specifically highlights the \"Price to earnings forward\" metric for the company. The content appears to be a financial data page from Trading", "url": "https://www.tradingview.com/symbols/FWB-5AX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T17:39:25", "published_display": "25 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Nuvalent, Inc. Class A \u2013 FWB:5AX", "summary": "This article provides financial information for Nuvalent, Inc. Class A (FWB:5AX), specifically its enterprise value to EBITDA forward. It notes that the market was closed with no trades. The data is made available through TradingView, sourcing information from ICE Data Services a", "url": "https://www.tradingview.com/symbols/FWB-5AX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T10:11:41", "published_display": "25 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK Unit Launches Tender Offer for Nuvalent Acquisition", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/gsk-unit-launches-tender-offer-160233037.html", "source_name": "MT Newswires", "published_at": "2026-06-24T16:02:33+00:00", "published_display": "24 Jun 2026 16:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s What the Acquisition of Nuvalent Means for Nuvation Bio (NUVB)", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/acquisition-nuvalent-means-nuvation-bio-184552044.html", "source_name": "Insider Monkey", "published_at": "2026-06-16T18:45:52+00:00", "published_display": "16 Jun 2026 18:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion", "summary": "", "url": "https://finance.yahoo.com/m/5ae71931-6430-3663-8e61-cb2c209f2b42/patent-cliff-predators%3A-gsk.html", "source_name": "MarketBeat", "published_at": "2026-06-11T16:25:00+00:00", "published_display": "11 Jun 2026 16:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Nuvalent (NUVL) Valuation After Strong Multi\u2011Year Share Price Gains", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent, a Nasdaq-listed bio company in the U.S., hit an all-time high on the news of the acquisiti..", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE52UEhZd21sUUpIRURZYWxTV01KUUZXOWVSS2p0RU51V2F2c2FxeDl0cUQwRF9menFOSE8tZXAzTlF4R1FYRGViM2h5aHNRdVE?oc=5", "source_name": "\ub9e4\uc77c\uacbd\uc81c", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPOW9vb05rR0ZGTFNPMmMxSEtma21pRTB3bUF4b3RTRFNCbVdOQ2RFYUZMakJUSTFTdFN4MllEb1c2NURoSE51M3U1SUlmVHNOMDZhQ0llZnJVaEk5VjNjQ1JVbV9ybWpjWHEtZmdZWThhYWxrQVZ3T3RSdTAxZjQtMUpjelh0d0g4cDdqTHNxdEstZnpuYWh1NdIBngFBVV95cUxNNkNZQ1VGZ1RjTEt1a1JoR1ZKaDNRWjdjNnU3X1dybFFlWkxTMUNJSm1BLWJlMWdGWE1iWXdKU1dEcGZjbmZvNXl5V3pScFNmQnZOZzhSdXhBU29ySklfUFliV05KWHJVZ2N2MUJNaDllTW1zZEkyZTY5eXhFUW52LTZqRFNTWmgzVGNGWXlDc0NIVG05ejJ6YzNKT1ZzQQ?oc=5", "source_name": "CNBC", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent Catapults To Record High On GSK's $10.6 Billion All-Cash Bid", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE5BS0dVcGhOTjZ3Ukt3ZFg2aFg1S1RmOVFpdDBLdmo0dUtFbF9FMy1UWEZ6MENEbFNTQmlNVGhEbTBoeUdBM2k0TnBpXzZNa291eEV4Y0xxLVkxNEhIZjB3T09aTW9IcFhfSHJwTXE3WDZyTkwtUzBXdEtoamJSZw?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK enters agreement to acquire Nuvalent, Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPTTc3SFlzWjNlX0Q2b0xBdnl5N1kzazBFeG9UWUF3YVVRTjR0VEIxY200Wk85QXdUUnhwVFdVV0hJYmpHcUFoTzVZdExfRUlIM0FxM1ZCQVZTQjEtOGoxZFFEdldJMTNPMExRbFBUR3dqdnJXa2pSWC1tMmtReWZpSndMaUJCMlU1a254V011SnNpMXc3RkE?oc=5", "source_name": "GSK US", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPVHFPVWp5ckQtdGRRYXFDSU1kMER6VlRhaC1tTkNzd0dBbWY5WmxZbFdQaG5fY3VVSFJtLWFvb3BPckoxbndhcGd6ZlNjbEI4akxBNkt0eVZucm1VVUpDSXlobHB5TUoxcTNUd2MzOHdmUE1KV1gwaEZBd05qMEdONkwxMzdlUWdyR3RJajVWMXNVMzd4bG03WlI4Um43V0NCbzJVb29RUzBrNzNQVWVkTUgxbl9TWWJ3YVRJS3VfUnEyWVMteEJEZDZR?oc=5", "source_name": "Reuters", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FTSE 100 down as GSK buys US drugmaker Nuvalent", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQa3VaVTQ0QWFuOFptM3hPazlzdzZROWFPRlZKb0lYYVZLZUE0bk5PazM3ajdIMDZOTnc1bWlIN2w0QWtsVWF6S2d2VXpMYWRlWU1ER0NuSXJaVmN1WlpzMkdMYkVGNmg1V2lQR1k3OGozZ1FRYmU2MS1EaUF0dk1rSWkyT1ZFc2VTTFo5TkFhalZOQ28zTDJybC1pTzFRTmZOOUE?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making the biggest moves premarket: GSK, Nuvalent, J.M. Smucker, SailPoint and more", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQTUlCa0loQmk3N0MyZU5XSHFwWEVkS0tJSk9hbHJuZlRXR0ZQSmFpYm9JcWNhc3diWWFxaVlPaFBxaDJoVGhqQmhFekNvcWVfRHdmZU5aQ2wwbWdnc3VDanQzUGFzS1Z1ZUljaEJ2b0tmcWJyRHpfVU00SnhNbEpLRXBaY0pLNGh2cEpGVGNKTTBkV2lYV0dOdS1Zb1U1Wmk5d3JFdGdYQmhRQ3VfWkV0a1ZtU1poaVZybzUtaEV3?oc=5", "source_name": "CNBC", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent Stock Hits All-Time High Following GSK's Buyout Offer", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQVVJia1pIUHJXb0o1aU9pZzlRb2FzVGRUbWJFakYzeFdiQTF2TUlPOUFXcGNIUXZYcGh5ckN0cGhoa1drbGN4M1BiQjdYMXhlamFLQTRLb1FnTEhaRWtwOWh6ckRZa0xYSElyVUNSNUtUTzF4dDFJMHBvTGRaRFVnR3lLMmtUa3pCa015amo5Z0hreUZCaHdGOHBR?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "London's FTSE 100 falls as GSK slides after Nuvalent deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxONEp2NVdzcTltLU9pRS1DZ2pzUDIyWDlfMXYxVVdfaWo5SkdZaHJwbmo1WHU0a0hWTHI4V3N0SnhyQ3cxVTdZSEQ5TEpPamY4UjFZVkJqNm1IODhzd2JNWUxGajhjWDM4S2dNd3JXMjFPUTVOX1lmb0Ntc3pnQ01GcEh6aUpXTmhRZUdGSGVUbGt2TmVCRU5MWVBYZmh5ajFwUklHME5wa195V0pYT1FJcVo5Wm0?oc=5", "source_name": "TradingView", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK\u2019s $10.6B Nuvalent takeover fails to impress investors as shares fall: here's why", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxNVE1LVWp0SE1MSGdCLU1OTFUxRks2Smo0TnJLSUk3dDZ5WDVSTktvTkJsam1VY3pRcWRBUmJIcTVrMWw1Z2VROHhwX2ZtNzFtaERwTXJIRVZQV1cxcFpBWU92WmlhNmFIM3NWV0oyV0RiLVJzYTRlYXBoNHhaOEhna1F1NDJWVUgwM0tneFllSUcwZGtWVFBDX2RFRktlR2FtOHNrRWdYc1A0TjZUUTRkSi1lN183M3lyNWIzcjZGRVlNUUZ6c1VKdERVTkZ0Z0M2Y1ZrbHJ3?oc=5", "source_name": "TradingView", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Nuvalent (NUVL) Have the Pipeline Depth to Justify Its Global Expansion Ambitions?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent ASCO 2026 Data Puts Neladalkib And Zidesamtinib In Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Deerfield holders cash out of Nuvalent (NUVL) at $124 per share", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPVkNPN1RRdXJWaWhvc2xLcnduRTEtb25zSk1CdnBHVzRkNTlRM1lZSThnQzJUaFRsNGstTnhsemRQdDhuMW02Zkc3Y0RWdkdwOUNmM3BTTWYxX0ZnM2xoTXV5c0d4Zmk2dmROZWViekgxTEhoQ3AzRWJvTnpNWU01RXBzeXgtOWhuaVdncUMxenRjNFFDWUpnSDZDcE1zRG9GcUtPdHlDdlY1QQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T19:27:52+00:00", "published_display": "17 Jul 2026 19:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deerfield group reports 0% ownership in Nuvalent (NUVL) Class A shares", "summary": "A Deerfield-affiliated investor group, led by James E. Flynn, has filed an amended Schedule 13G (Amendment No. 7) for Nuvalent, Inc. (NUVL). The filing indicates that the group now beneficially owns 0 shares of Nuvalent Class A common stock, translating to 0.0% of the class. This", "url": "https://www.stocktitan.net/sec-filings/NUVL/schedule-13g-a-nuvalent-inc-amended-passive-investment-disclosure-558e68760ceb.html", "source_name": "Stock Titan", "published_at": "2026-07-17T19:39:53", "published_display": "17 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent, Inc. (NUVL) director\u2019s RSUs and options canceled for $124 cash rights in GSK merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOYXFtRF95X3lLRmxCbHJLRVNMR0hrU1BTNUl5RDRDbm51OWNaTm5rMUxCWVJpSmxNUVB4RUp1bmxHblBUWGtXSGFoOU9sc1Z5dVpkcVNVbmJTTGpfQW80eEo3YjlqdTV0MnJRaHBMSDhwOXVDRktMcVcxOHNCVmpMR2NUSXJlY05sVEVmYXBLdkVOY3hqbUxsS2NXSTlONzYxcnU0bGE2ZUhwQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T23:03:48+00:00", "published_display": "15 Jul 2026 23:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK\u2019s $124-per-share Nuvalent, Inc. (NUVL) deal reshapes CMO equity", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQS1R5THVDQkpLRWlVQ3g1ajR6Y01qcF9YU3pOQ3pmb2xZekI0Nks4bkhlRXlwa3R6NlFoXzVRbVRQNHBUejRYOFZkRHlMSXp5ZTRqb05Hek5NdnhRN2dCS1BFV1dHZmdyY1BwZTlXVkZmODJZdnd0N2Mtc1pVNjdyY1dqMDN6Rm5kMkVBcWtzWjdUY2ZoY0RiUWY0T1ktNTdHUlNBbTRVenVtQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T22:58:19+00:00", "published_display": "15 Jul 2026 22:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent, Inc. (NUVL) officer exits via $124-per-share cash tender", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQU0FmTkdEOXF4U0VJZW5HaWRxTnFqQkNJeE5KTjBnZkF4dGJ0d1VpczRHcFZURlY5czFkRDhud3R2Vmp0WmVJM0I2RlFlaUVkM25ySTAya2Rib2lsazhDMTBOZU1mNGJvaHpIeUs0ZmloMzJTdktTZUxaZFNyNldKYXRlN3N4QjdqRXVHS1BXYS13NVlZQlVHM0ZUUU9vQkhsQ2c3dVV3a3Nudw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T22:51:21+00:00", "published_display": "15 Jul 2026 22:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NUVL) CLO exits equity via $124-per-share GSK tender offer and merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPb0NKb3k4MV9jUGZ3Qk1yc19ORjBKZ0g1VW5LM1hQLUw3U3A1bHZmbW5SckhJeDBabmljcDR2XzhHYzVxeWJtZTNvVmZRNGJnSWlQbXZ0MnJncVp3WGV4dGx2TmxrM1ZpVUQzZXlKVmNDQkNHeTdLMlRRbllvRkhsVFRQTklubHNtckNkbWpuY3c4eUtjRTRiQzg1ZEllTzV4VmNoeVpBaEJHZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T22:42:56+00:00", "published_display": "15 Jul 2026 22:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Nuvalent, Inc. Insider Trading Activity", "summary": "Nuvalent, Inc.'s Chief Development Officer, Darlene Noci, reported significant merger-related equity transactions. These involved the tender of 17,017 shares of Class A Common Stock at $124.00 per share as part of a tender offer by a GlaxoSmithKline affiliate, which was followed ", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-ca243ab0ebcf.html", "source_name": "Stock Titan", "published_at": "2026-07-15T23:10:23", "published_display": "15 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent, Inc. (NUVL) CEO equity converted in $124 GSK tender offer", "summary": "Nuvalent, Inc.'s President and CEO, James Richard Porter, converted all his equity holdings, including 203,529 Class A shares, RSUs, PSUs, and stock options, into cash as part of a tender offer and subsequent merger with an affiliate of GSK plc. The shares were tendered at $124.0", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-0ecfb9620971.html", "source_name": "Stock Titan", "published_at": "2026-07-15T23:10:23", "published_display": "15 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent, Inc. (NUVL) director tenders stock in $124 GSK cash buyout", "summary": "Nuvalent, Inc. director Sapna Srivastava has disposed of equity tied to a cash tender offer and merger with a GlaxoSmithKline affiliate. She tendered 5,146 shares of Class A Common Stock at $124.00 per share, and had 3,444 restricted stock units and several stock option grants ca", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-c04b38e362af.html", "source_name": "Stock Titan", "published_at": "2026-07-15T23:10:23", "published_display": "15 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent, Inc. (NUVL) CFO details tender offer and award cash-outs", "summary": "Nuvalent, Inc. CFO Alexandra Balcom reported significant equity transactions stemming from a merger with a GlaxoSmithKline affiliate. She tendered 44,433 shares for $124.00 per share and saw restricted stock units and stock options cancelled and converted into cash at the same of", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-c76d095bc323.html", "source_name": "Stock Titan", "published_at": "2026-07-15T23:10:23", "published_display": "15 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NASDAQ: NUVL) director logs $124 tender-offer disposals", "summary": "Nuvalent Director Wheeler Cameron reported the disposition of 5,146 Class A shares at $124.00 each, along with 3,444 RSUs and several stock option grants, related to GlaxoSmithKline's tender offer and subsequent merger. These transactions resulted in Cameron's reported holdings i", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-691071d94372.html", "source_name": "Stock Titan", "published_at": "2026-07-15T22:10:23", "published_display": "15 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NUVL) director exits equity as GSK affiliate pays $124 per share", "summary": "Nuvalent's director, Grant C. Bogle, cashed out his equity holdings in connection with the company's acquisition by a GlaxoSmithKline affiliate. The acquisition involved a tender offer at $124.00 per share, resulting in Nuvalent becoming a wholly owned subsidiary. Bogle disposed ", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-e1cd69ad784e.html", "source_name": "Stock Titan", "published_at": "2026-07-15T22:10:23", "published_display": "15 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NUVL) director equity cashed out in $124 GSK buyout", "summary": "Nuvalent's director, Anna Protopapas, reported dispositions of her equity holdings in connection with GlaxoSmithKline's tender offer to acquire all outstanding Nuvalent stock for $124.00 per share. Her 5,146 Class A shares, 3,444 restricted stock units, and multiple stock options", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-2f5438f80665.html", "source_name": "Stock Titan", "published_at": "2026-07-15T22:10:23", "published_display": "15 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK Completes $10.6 Billion Acquisition of Nuvalent", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/gsk-completes-10-6-billion-141637255.html", "source_name": "MT Newswires", "published_at": "2026-07-15T14:16:37+00:00", "published_display": "15 Jul 2026 14:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GlaxoSmithKline LLC closes $10.6B Nuvalent (NUVL) all-cash tender and merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOSm54SkI0VWRyYVh5Q0M1RTRsMlVLejNJMVg2QUJiQjdKRDNRc0UtNEVONzhfbG5jUUxrZHYzNWxEZzdZNFYzMGp6NlZzNGdxTHpYUXBkTy1namQ1RFNScXRfSDNRQWJWRHVzdXE4SVFLVkI4SFhXcEF5anZEc1lGVlVRajV4RmZtNDE5dWxlcllscjBGeFl4V0lQcVlHWmd6NVpB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T13:03:50+00:00", "published_display": "15 Jul 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent Inc. (NASDAQ: NUVL) Holders Tender 91% in $124 GSK Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNWXVyanV2VXQzYXZYNlBJS2ZoWUxOZUZCRHNrdUZzNm1ZSUdhOE1JYlh5WDJHaVFLVzMtWGR4NzRYdXAyZ1dkcTdXU0JEd2ZrVXQ0ZmxjSXFUUUZmTmlWZnN2X2g1WnZPVXNWY3FYUURZODZOQTE2TDBpLW9PYXFaZXpQc3pjaGw2d2RYSnFRZnZHVGx1U3JZbDZtY0Z0cjBOVTFzSVhNdE45bW5XWHltNDZwc0tuTjZT?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T13:02:07+00:00", "published_display": "15 Jul 2026 13:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NASDAQ: NUVL) moves to remove Class A stock from Nasdaq", "summary": "Nuvalent, Inc. (NASDAQ: NUVL) has filed a Form 25 to delist its Class A Common Stock from the Nasdaq Stock Market LLC, indicating a voluntary withdrawal from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. This action signifies that both Nasda", "url": "https://www.stocktitan.net/sec-filings/NUVL/25-nse-nuvalent-inc-sec-filing-f4ab8a359c16.html", "source_name": "Stock Titan", "published_at": "2026-07-15T13:43:45", "published_display": "15 Jul 2026 13:43", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NASDAQ: NUVL) tender offer clears $124 cash merger path", "summary": "Nuvalent, Inc. announced the final results of the tender offer by Harmony Row Acquisition Co., a subsidiary of GlaxoSmithKline LLC, to acquire all outstanding shares for $124.00 per share. Approximately 91.3% of Nuvalent's shares were validly tendered, satisfying the minimum tend", "url": "https://www.stocktitan.net/sec-filings/NUVL/sc-14d9-a-nuvalent-inc-amended-tender-offer-recommendation-f25304ac2498.html", "source_name": "Stock Titan", "published_at": "2026-07-15T12:43:45", "published_display": "15 Jul 2026 12:43", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent CSO Henry Pelish sells $261,362 in stock By Investing.com", "summary": "Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold 2,111 shares of Class A Common Stock for $261,362, executed under a Rule 10b5-1 trading plan to cover tax obligations. This sale occurred as Nuvalent shares approached a 52-week high, coinciding with GSK's announced acqui", "url": "https://m.au.investing.com/news/stock-market-news/nuvalent-cso-henry-pelish-sells-261362-in-stock-93CH-4528403?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-07-11T02:39:46", "published_display": "11 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent CSO Henry Pelish sells $261,362 in stock", "summary": "Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold 2,111 shares of the company's Class A Common Stock for $261,362 on July 9, 2026. This transaction was part of a pre-established trading plan, often used to cover tax obligations from equity awards, and occurred as Nuvalen", "url": "https://m.uk.investing.com/news/stock-market-news/nuvalent-cso-henry-pelish-sells-261362-in-stock-93CH-4766405?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-10T21:10:59", "published_display": "10 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent, Inc. (NUVL) \u2014 HSR waiting period cleared; $124/ share cash offer remains subject to closing conditions", "summary": "Nuvalent, Inc. (NUVL) announced that the Hart-Scott-Rodino (HSR) Act waiting period for its tender offer with Harmony Row Acquisition Co./GlaxoSmithKline LLC expired on July 9, 2026. This satisfies one key closing condition for the $124 per share cash offer, though the overall of", "url": "https://www.stocktitan.net/sec-filings/NUVL/sc-14d9-a-nuvalent-inc-amended-tender-offer-recommendation-e9e43c76efb1.html", "source_name": "Stock Titan", "published_at": "2026-07-10T19:39:46", "published_display": "10 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent Inc. (NUVL) \u2014 GSK\u2019s Harmony Row clears HSR; $124 cash offer proceeds", "summary": "The article reports that the HSR waiting period for GSK\u2019s Harmony Row Acquisition Co.'s tender offer to acquire Nuvalent Inc. (NUVL) has expired, satisfying a key regulatory condition. Harmony Row Acquisition Co., GlaxoSmithKline LLC, and GSK plc are offering $124.00 per share in", "url": "https://www.stocktitan.net/sec-filings/NUVL/sc-to-t-a-nuvalent-inc-amended-third-party-tender-offer-626639507bad.html", "source_name": "Stock Titan", "published_at": "2026-07-10T13:11:25", "published_display": "10 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NUVL (NASDAQ: NUVL) insider sale notice for 2,111 Class A shares", "summary": "Nuvalent, Inc. (NASDAQ: NUVL) has filed a Form 144 indicating a proposed sale of 2,111 shares of Class A Common Stock, valued at $261,358.43, related to Restricted Stock Unit Vesting on July 9, 2026. The filing also revealed that 3,093 shares, totaling $323,169.86, were sold in t", "url": "https://www.stocktitan.net/sec-filings/NUVL/144-nuvalent-inc-sec-filing-58d06110a8e9.html", "source_name": "Stock Titan", "published_at": "2026-07-10T08:41:59", "published_display": "10 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent president and CEO Porter sells $3.7m in shares By Investing.com", "summary": "Nuvalent (NASDAQ:NUVL) President and CEO James Richard Porter sold 30,000 shares of Class A Common Stock for approximately $3.71 million on July 6, 2026, while concurrently exercising options to acquire 30,000 shares. This transaction occurred as the stock traded near its 52-week", "url": "https://m.in.investing.com/news/stock-market-news/nuvalent-president-and-ceo-porter-sells-37m-in-shares-93CH-5488140?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-07-08T23:11:12", "published_display": "08 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NUVL) CEO executes 30K-share option exercise and open-market sale under 10b5-1 plan", "summary": "Nuvalent, Inc. President and CEO James Richard Porter executed a pre-planned transaction, exercising options for 30,000 shares of Class A Common Stock at $18.93 per share and simultaneously selling those 30,000 shares in the open market at a weighted average price of $123.72 per ", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-e51a3734a597.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:11:12", "published_display": "08 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC discloses 1,417,590 shares in Nuvalent (NASDAQ: NUVL)", "summary": "FMR LLC has filed an Amendment No. 5 to Schedule 13G/A, revealing a beneficial ownership of 1,417,590.47 shares of Nuvalent Inc. Class A common stock, which accounts for 1.9% of the total class. The filing indicates sole voting power over 1,402,750 shares and sole dispositive pow", "url": "https://www.stocktitan.net/sec-filings/NUVL/schedule-13g-a-nuvalent-inc-amended-passive-investment-disclosure-7149bc8d4077.html", "source_name": "Stock Titan", "published_at": "2026-07-08T14:09:34", "published_display": "08 Jul 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent(NUVL.US) Officer Sells US$3.71 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPWF8wZ1NDanFCWGRyWVZjd2VtSFZlR0dXZ0lqbUs2akRMZ2V5NVR4RmVuLXFmRmVmbk1KSmR0T2R6MUtEdHNuXzhBVnpCTDRzaF9xWGJXZ0dKWWNnclhuNjFoeVMtcWQ5Y1J1MEVUZEpKTjNwZXROckZXai1RWVFWekJidnNuVzVaSlZUZWlsYW1qcFpTVUI4ZWVubFBFQQ?oc=5", "source_name": "Moomoo", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NUVL) supplements disclosures as $124 cash offer proceeds", "summary": "Nuvalent, Inc. amended its Schedule 14D-9 to provide supplementary disclosures regarding the recommended $124.00 per share cash tender offer by a GlaxoSmithKline subsidiary. This amendment includes additional financial details, management forecasts, and Centerview valuation analy", "url": "https://www.stocktitan.net/sec-filings/NUVL/sc-14d9-a-nuvalent-inc-amended-tender-offer-recommendation-6dfc2781654d.html", "source_name": "Stock Titan", "published_at": "2026-07-07T19:09:34", "published_display": "07 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NUVL) CFO sells 11,430 shares and exercises options under plan", "summary": "Nuvalent, Inc.'s CFO, Alexandra Balcom, exercised stock options for 11,430 shares and subsequently sold the same number of shares (11,430) at a weighted average price of $123.58 per share. These transactions were executed on July 1, 2026, under a Rule 10b5-1 trading plan adopted ", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-03b6d980e834.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:12:11", "published_display": "06 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent (NUVL) CDO exercises options and sells 23,000 shares", "summary": "Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options for 23,000 shares of Class A Common Stock on July 1, 2026, at exercise prices of $72.35 and $18.93 per share. Immediately after, she sold all 23,000 shares in an open-market transaction at a weighted aver", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-8096d5f30480.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:12:11", "published_display": "06 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NUVL (NASDAQ: NUVL) Form 144 lists insider sale of Class A Common", "summary": "Nuvalent, Inc. (NUVL) has filed a Form 144 with the SEC, indicating a proposed insider sale of Class A Common shares via NQ Stock Options, with J.P. Morgan Securities LLC named as the broker. The filing also details multiple past sales attributed to Alexandra Balcom, occurring be", "url": "https://www.stocktitan.net/sec-filings/NUVL/144-nuvalent-inc-sec-filing-99795911a530.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:35", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider at Nuvalent (NUVL) exercises options and sells 5,500 shares", "summary": "Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options to acquire 5,500 shares at $27.85 per share and subsequently sold those 5,500 shares in the open market for a weighted average price of $123.51 per share. These transactions were conducted under a pre-arr", "url": "https://www.stocktitan.net/sec-filings/NUVL/form-4-nuvalent-inc-insider-trading-activity-b000314d9e63.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:35", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share", "summary": "GSK plc has launched a tender offer to acquire Nuvalent, Inc. for $124 per share in cash, following a merger agreement signed on June 9, 2026. This move represents a significant step in GSK's strategic acquisitions. Additionally, GSK's ViiV Healthcare has introduced the PrEP Wisd", "url": "https://www.insidermonkey.com/blog/gsk-plc-gsk-launches-tender-offer-to-acquire-nuvalent-inc-for-124-per-share-1792040/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-30T13:40:25", "published_display": "30 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Nuvalent, Inc. Class A \u2013 FWB:5AX", "summary": "This article provides financial information for Nuvalent, Inc. Class A, specifically its enterprise value to revenue (forward) metric. The content indicates that the market was closed and no trades were made for this stock. The data is provided by ICE Data Services and FactSet Re", "url": "https://www.tradingview.com/symbols/FWB-5AX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T17:40:53", "published_display": "28 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Nuvalent, Inc. Class A \u2013 FWB:5AX", "summary": "This article provides financial information for Nuvalent, Inc. Class A, traded on the Frankfurt Stock Exchange (FWB:5AX). It specifically highlights the \"Price to book forward\" metric. The content itself seems to be a placeholder or a snippet from a financial data platform, showi", "url": "https://www.tradingview.com/symbols/FWB-5AX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T01:40:55", "published_display": "26 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent, Inc. Class A Actuals & Estimates (NASDAQ:NUVL)", "summary": "This article provides an overview of Nuvalent, Inc. (NASDAQ: NUVL) stock's actuals and estimates, including its current stock price, historical performance, analyst forecasts, and various financial metrics. It details the company's market capitalization, earnings per share, reven", "url": "https://www.tradingview.com/symbols/NASDAQ-NUVL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:39:25", "published_display": "26 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Nuvalent, Inc. Class A \u2013 FWB:5AX", "summary": "This article provides financial information for Nuvalent, Inc. Class A, traded on the Frankfurt Stock Exchange under the symbol FWB:5AX. It specifically highlights the \"Price to earnings forward\" metric for the company. The content appears to be a financial data page from Trading", "url": "https://www.tradingview.com/symbols/FWB-5AX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T17:39:25", "published_display": "25 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Nuvalent, Inc. Class A \u2013 FWB:5AX", "summary": "This article provides financial information for Nuvalent, Inc. Class A (FWB:5AX), specifically its enterprise value to EBITDA forward. It notes that the market was closed with no trades. The data is made available through TradingView, sourcing information from ICE Data Services a", "url": "https://www.tradingview.com/symbols/FWB-5AX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T10:11:41", "published_display": "25 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK Unit Launches Tender Offer for Nuvalent Acquisition", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/gsk-unit-launches-tender-offer-160233037.html", "source_name": "MT Newswires", "published_at": "2026-06-24T16:02:33+00:00", "published_display": "24 Jun 2026 16:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s What the Acquisition of Nuvalent Means for Nuvation Bio (NUVB)", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/acquisition-nuvalent-means-nuvation-bio-184552044.html", "source_name": "Insider Monkey", "published_at": "2026-06-16T18:45:52+00:00", "published_display": "16 Jun 2026 18:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion", "summary": "", "url": "https://finance.yahoo.com/m/5ae71931-6430-3663-8e61-cb2c209f2b42/patent-cliff-predators%3A-gsk.html", "source_name": "MarketBeat", "published_at": "2026-06-11T16:25:00+00:00", "published_display": "11 Jun 2026 16:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Nuvalent (NUVL) Valuation After Strong Multi\u2011Year Share Price Gains", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent, a Nasdaq-listed bio company in the U.S., hit an all-time high on the news of the acquisiti..", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE52UEhZd21sUUpIRURZYWxTV01KUUZXOWVSS2p0RU51V2F2c2FxeDl0cUQwRF9menFOSE8tZXAzTlF4R1FYRGViM2h5aHNRdVE?oc=5", "source_name": "\ub9e4\uc77c\uacbd\uc81c", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPOW9vb05rR0ZGTFNPMmMxSEtma21pRTB3bUF4b3RTRFNCbVdOQ2RFYUZMakJUSTFTdFN4MllEb1c2NURoSE51M3U1SUlmVHNOMDZhQ0llZnJVaEk5VjNjQ1JVbV9ybWpjWHEtZmdZWThhYWxrQVZ3T3RSdTAxZjQtMUpjelh0d0g4cDdqTHNxdEstZnpuYWh1NdIBngFBVV95cUxNNkNZQ1VGZ1RjTEt1a1JoR1ZKaDNRWjdjNnU3X1dybFFlWkxTMUNJSm1BLWJlMWdGWE1iWXdKU1dEcGZjbmZvNXl5V3pScFNmQnZOZzhSdXhBU29ySklfUFliV05KWHJVZ2N2MUJNaDllTW1zZEkyZTY5eXhFUW52LTZqRFNTWmgzVGNGWXlDc0NIVG05ejJ6YzNKT1ZzQQ?oc=5", "source_name": "CNBC", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent Catapults To Record High On GSK's $10.6 Billion All-Cash Bid", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE5BS0dVcGhOTjZ3Ukt3ZFg2aFg1S1RmOVFpdDBLdmo0dUtFbF9FMy1UWEZ6MENEbFNTQmlNVGhEbTBoeUdBM2k0TnBpXzZNa291eEV4Y0xxLVkxNEhIZjB3T09aTW9IcFhfSHJwTXE3WDZyTkwtUzBXdEtoamJSZw?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK enters agreement to acquire Nuvalent, Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPTTc3SFlzWjNlX0Q2b0xBdnl5N1kzazBFeG9UWUF3YVVRTjR0VEIxY200Wk85QXdUUnhwVFdVV0hJYmpHcUFoTzVZdExfRUlIM0FxM1ZCQVZTQjEtOGoxZFFEdldJMTNPMExRbFBUR3dqdnJXa2pSWC1tMmtReWZpSndMaUJCMlU1a254V011SnNpMXc3RkE?oc=5", "source_name": "GSK US", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPVHFPVWp5ckQtdGRRYXFDSU1kMER6VlRhaC1tTkNzd0dBbWY5WmxZbFdQaG5fY3VVSFJtLWFvb3BPckoxbndhcGd6ZlNjbEI4akxBNkt0eVZucm1VVUpDSXlobHB5TUoxcTNUd2MzOHdmUE1KV1gwaEZBd05qMEdONkwxMzdlUWdyR3RJajVWMXNVMzd4bG03WlI4Um43V0NCbzJVb29RUzBrNzNQVWVkTUgxbl9TWWJ3YVRJS3VfUnEyWVMteEJEZDZR?oc=5", "source_name": "Reuters", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FTSE 100 down as GSK buys US drugmaker Nuvalent", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQa3VaVTQ0QWFuOFptM3hPazlzdzZROWFPRlZKb0lYYVZLZUE0bk5PazM3ajdIMDZOTnc1bWlIN2w0QWtsVWF6S2d2VXpMYWRlWU1ER0NuSXJaVmN1WlpzMkdMYkVGNmg1V2lQR1k3OGozZ1FRYmU2MS1EaUF0dk1rSWkyT1ZFc2VTTFo5TkFhalZOQ28zTDJybC1pTzFRTmZOOUE?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making the biggest moves premarket: GSK, Nuvalent, J.M. Smucker, SailPoint and more", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQTUlCa0loQmk3N0MyZU5XSHFwWEVkS0tJSk9hbHJuZlRXR0ZQSmFpYm9JcWNhc3diWWFxaVlPaFBxaDJoVGhqQmhFekNvcWVfRHdmZU5aQ2wwbWdnc3VDanQzUGFzS1Z1ZUljaEJ2b0tmcWJyRHpfVU00SnhNbEpLRXBaY0pLNGh2cEpGVGNKTTBkV2lYV0dOdS1Zb1U1Wmk5d3JFdGdYQmhRQ3VfWkV0a1ZtU1poaVZybzUtaEV3?oc=5", "source_name": "CNBC", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent Stock Hits All-Time High Following GSK's Buyout Offer", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQVVJia1pIUHJXb0o1aU9pZzlRb2FzVGRUbWJFakYzeFdiQTF2TUlPOUFXcGNIUXZYcGh5ckN0cGhoa1drbGN4M1BiQjdYMXhlamFLQTRLb1FnTEhaRWtwOWh6ckRZa0xYSElyVUNSNUtUTzF4dDFJMHBvTGRaRFVnR3lLMmtUa3pCa015amo5Z0hreUZCaHdGOHBR?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "London's FTSE 100 falls as GSK slides after Nuvalent deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxONEp2NVdzcTltLU9pRS1DZ2pzUDIyWDlfMXYxVVdfaWo5SkdZaHJwbmo1WHU0a0hWTHI4V3N0SnhyQ3cxVTdZSEQ5TEpPamY4UjFZVkJqNm1IODhzd2JNWUxGajhjWDM4S2dNd3JXMjFPUTVOX1lmb0Ntc3pnQ01GcEh6aUpXTmhRZUdGSGVUbGt2TmVCRU5MWVBYZmh5ajFwUklHME5wa195V0pYT1FJcVo5Wm0?oc=5", "source_name": "TradingView", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK\u2019s $10.6B Nuvalent takeover fails to impress investors as shares fall: here's why", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxNVE1LVWp0SE1MSGdCLU1OTFUxRks2Smo0TnJLSUk3dDZ5WDVSTktvTkJsam1VY3pRcWRBUmJIcTVrMWw1Z2VROHhwX2ZtNzFtaERwTXJIRVZQV1cxcFpBWU92WmlhNmFIM3NWV0oyV0RiLVJzYTRlYXBoNHhaOEhna1F1NDJWVUgwM0tneFllSUcwZGtWVFBDX2RFRktlR2FtOHNrRWdYc1A0TjZUUTRkSi1lN183M3lyNWIzcjZGRVlNUUZ6c1VKdERVTkZ0Z0M2Y1ZrbHJ3?oc=5", "source_name": "TradingView", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Nuvalent (NUVL) Have the Pipeline Depth to Justify Its Global Expansion Ambitions?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvalent ASCO 2026 Data Puts Neladalkib And Zidesamtinib In Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 104, "total_relevant": 65, "sentiment_summary": {"positive": 12, "negative": 4, "neutral": 49, "score": 53, "total": 65, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 18.1, "count": 31}, {"event": "deals", "label": "Deals and strategy", "weight": 10.45, "count": 19}, {"event": "earnings", "label": "Earnings", "weight": 5.36, "count": 12}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}], "positive_events": 12, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 123.96, "latest_week": "2026-07-17", "one_week_move": 0.0, "four_week_move": 0.4, "twelve_week_move": 18.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.129096, "market_dynamics_buy_signal": false, "relative_strength": 12.956016, "fair_value_gap": 50.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 53.8254, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, +0.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 51, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 27}, {"label": "TradingView", "count": 7}, {"label": "Market source", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "MT Newswires", "count": 2}, {"label": "Insider Monkey", "count": 2}, {"label": "CNBC", "count": 2}, {"label": "Investing.com Australia", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Deals and strategy", "count": 19}, {"label": "Earnings", "count": 12}, {"label": "Balance sheet", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.0% over one week, +0.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Deerfield holders cash out of Nuvalent (NUVL) at $124 per share"}], "updated_at": "2026-07-22T09:42:47.141057+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}